Therapy News and Research

RSS

Scientists aim to develop a gene-targeting, antiviral agent against COVID-19

A team of scientists from Stanford University is working with researchers at the Molecular Foundry, a nanoscience user facility located at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab), to develop a gene-targeting, antiviral agent against COVID-19.

4 Jun 2020

Potential new immunotherapy for critical COVID-19

Researchers at the Chongqing Medical University in China have identified a cytokine that could serve as a potential candidate for treating patients with severe coronavirus disease 2019 (COVID-19).

4 Jun 2020

Exploring the molecular landscape of the aortic niche and beyond

Researchers from the group of Catherine Robin at the Hubrecht Institute characterized the molecular landscape of the aorta that supports the generation of the first Hematopoietic Stem Cells (HSCs) in the embryo.

4 Jun 2020

Researchers decipher deadly bacterial infection in pigs

The Clostridium perfringens bacterium is part of the large Clostridium genus which can cause various fatal illnesses in animals and humans.

4 Jun 2020

Nox4 protein can be used as a marker to predict untreatable kidney cancer

A team of researchers from The University of Texas Health Science Center at San Antonio confirmed the role of a certain protein in the development of high-grade kidney cancer.

4 Jun 2020

New therapeutic strategies for treating lung cancer

The international study "Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures", recently published in the scientific journal Nature Communication, has taken a further step in the development of new therapeutic strategies to treat lung cancer.

4 Jun 2020

In hard-hit areas, COVID’s ripple effects strain mental health care systems

In late March, Marcell's girlfriend took him to the emergency room at Henry Ford Wyandotte Hospital, about 11 miles south of Detroit.

4 Jun 2020

World’s first study of potential antibody therapy to fight COVID-19 begins in humans

Eli Lilly and Company today announced patients have been dosed in the world’s first study of a potential antibody treatment designed to fight COVID-19.

4 Jun 2020

Study reveals opportunity to improve outcomes in young children with concussion

Head injuries that lead to concussions can happen at any age, and children impacted by concussions have different needs and recovery patterns.

4 Jun 2020

Researchers treat TMC1-related deafness with gene therapy

When Wei Hsi (Ariel) Yeh was a young undergraduate student, one of her close friends went from normal hearing to complete deafness in the span of one month.

4 Jun 2020

Study says vitamin-magnesium combo may reduce severity of COVID-19 in seniors

The COVID-19 pandemic that began in late December 2019 has spread to over 188 countries and territories, causing over 6.5 million cases and 385,000 deaths. With no effective therapeutic COVID-19 drug or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in sight, researchers are exploring different strategies to limit its spread and mortality.

4 Jun 2020

Using advanced microscopy techniques to see single molecules of telomerase in living cells

Canadian scientists have achieved a first in the study of telomerase, an essential enzyme implicated in aging and cancer.

3 Jun 2020

New technique opens the door to treating genetic forms of hearing loss

Using a new genetic engineering technique, known as base editing, researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard, have restored hearing in mice with a known recessive genetic mutation.

3 Jun 2020

AFFiRiS announces preclinical results of monoclonal antibody mAB C6-17 in Huntington's

AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies, today announced that detailed preclinical results with its monoclonal antibody mAB C6-17 to treat Huntington's Disease were published in the peer-reviewed journal Neurobiology of Disease.

3 Jun 2020

Trastuzumab emtansine as a preferred second-line choice after horizontal dual blockade

Volume 11, Issue 22 of Oncotarget reported that despite relevant medical advancements, metastatic breast cancer remains an incurable disease.

3 Jun 2020

Discharge-ready patients still breathing out SARS-CoV-2 particles, finds study

In just five months, the COVID-19 paralyzed huge cities, confined billions to their homes, and brought economic activity to a standstill in much of the world. Tens of thousands of patients became critically ill, overwhelming healthcare facilities. Even as many recovered and were ready to go home, a new study published in May 2020 on the preprint server medRxiv reports that a significant number of patients ready to go home still have virus particles in their exhaled breath.

3 Jun 2020

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy.

3 Jun 2020